U
PLX icon

UBS’s Protalix BioTherapeutics PLX Stock Holding History

UBS’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-200
Closed -$7K – 10652
2014
Q2 		$7K Hold
200
– – ﹤0.01% 9240
2014
Q1 		$9K Sell
200
-710
-78% -$33.1K ﹤0.01% 9021
2013
Q4 		$35K Sell
910
-34,570
-97% -$1.46M ﹤0.01% 7439
2013
Q3 		$1.61M Sell
35,480
-590
-2% -$30.3K ﹤0.01% 2827
2013
Q2 		$1.77M Buy
+36,070
New +$1.91M ﹤0.01% 2678

Other funds holding PLX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MTWSIF
Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return
BG
BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

UBS's PLX Position: Q3 2014 in Review

UBS reduced its Protalix BioTherapeutics (PLX) stake by 53% in Q3 2014, selling an estimated $2.59K and leaving 80 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #10008.

UBS first reported a position in PLX in Q2 2013 and has held it in 6 quarters since. The position peaked at $1.09M in Q3 2013. 43 funds tracked by Wall St. Rank hold PLX as of Q3 2014.

  • UBS held 80 shares of Protalix BioTherapeutics worth $2K as of Q3 2014.
  • UBS sold 90 Protalix BioTherapeutics shares in Q3 2014, an estimated $2.59K.
  • Protalix BioTherapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #10008 holding.
  • UBS first reported a position in Protalix BioTherapeutics in Q2 2013 and has held it in 6 quarters since.
  • UBS's Protalix BioTherapeutics position peaked at $1.09M in Q3 2013.
  • 43 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.